Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Coagulation

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Global perspectives on the core elements of Antithrombotic Stewardship in hospital.

Thrombosis research·2026

Same author

Responsible preoperative opioid use for hip or knee arthroplasty (OpioidHALT): a protocol for a randomised clinical trial of pharmacist-partnered opioid tapering prior to hip or knee arthroplasty.

BMJ open·2026

Same author

Real-Time Evaluation of a Large Language Model for Clinical Practice Guideline Development.

Critical care explorations·2026

Same author

Virtue ethics for pharmacists: A call to action to develop and exercise.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Same author

Balance Versus Bias: Correcting Misinformation About the 2025 ATS Community-Acquired Pneumonia Guidelines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Gene-Genie! A web-based artificial intelligence platform supporting site preparedness for gene therapy.

Journal of the American Pharmacists Association : JAPhA·2026

Search research articles

Related Experiment Video

Updated: May 31, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Prothrombin complex concentrate for critical bleeding.

Asad E Patanwala¹, Nicole M Acquisto, Brian L Erstad

¹College of Pharmacy, University of Arizona, Phoenix, AZ, USA. Patanwala@pharmacy.arizona.edu

The Annals of Pharmacotherapy

|July 7, 2011

Summary

This summary is machine-generated.

Prothrombin complex concentrate (PCC) is a safe and effective alternative to fresh frozen plasma (FFP) for reversing vitamin K antagonist therapy. More comparative trials are needed to assess hemostatic effects.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 31, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

Hematology
Pharmacology

Background:

Prothrombin complex concentrate (PCC) is increasingly used for bleeding management.
Evidence for its efficacy in non-hemophilic patients is under review.

Purpose of the Study:

To review evidence supporting prothrombin complex concentrate (PCC) use as a hemostatic agent in non-hemophilic individuals.
To compare PCC with fresh frozen plasma (FFP) and recombinant factor VIIa.

Main Methods:

Literature search of Ovid/MEDLINE and Cochrane Central Register.
Included comparative studies of PCC versus FFP or recombinant factor VIIa for bleeding management.
Focused on patients without hemophilia.

Main Results:

PCC is recommended for serious bleeding from vitamin K antagonist therapy, showing safety and effectiveness.
PCC offers prompt international normalized ratio (INR) reduction compared to FFP.
Insufficient evidence exists for PCC in hepatic failure or traumatic hemorrhage.
PCC has a lower volume requirement than FFP but carries a risk of thromboembolic complications.

Conclusions:

PCC is a safe, effective alternative to FFP for rapid INR reversal in patients on vitamin K antagonists.
PCC may be advantageous in volume-restricted patients.
Further comparative trials are essential to evaluate hemostatic efficacy of PCC, FFP, and recombinant factor VIIa.